The role of a peripheral dopamine-antagonist (Motilium) in improving the tolerance to steroidal and non-steroidal anti-inflammatory agents.
Domperidone protective therapy has been applied in 50 patients suffering from locomotor disease, who responded with dyspeptic complaints to the steroidal and non-steroidal antiphlogistic therapies which meant a risk of the activation of an earlier gastro-intestinal disease. The basic therapy could be applied to 80% of patients due to the Motilium protection because of the favourable changes in gastro-intestinal symptoms. Since domperidone is well tolerated by the patients and it does not yield higher risks, it's use is highly recommended as a protective therapy as well.
Zahumenszky
Z
Z
Department I, National Institute of Rheumatology and Physiotherapy, Budapest.
Farkas
E
E
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D004294:Domperidone / Q000627:therapeutic use*; D004361:Drug Tolerance; D004415:Dyspepsia / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D013256:Steroids
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D013256:Steroids; D004294:Domperidone